Declining Cancer Screening Rates Prompt Interest in New Detection Methods
A survey indicates a decline in cancer screening rates, contrasted by growing interest in at-home and multi-cancer early detection tests.
A survey indicates a decline in cancer screening rates, contrasted by growing interest in at-home and multi-cancer early detection tests.
ClearNote Health has received UKCA marking for its Avantect Pancreatic Cancer Test, enabling commercial availability in the UK.
CAP has updated 23 cancer protocols to align with the latest standards from AJCC and WHO, enhancing diagnostic precision and patient care.
It can take over a decade for unnecessary cancer screenings to significantly decline after updated guidelines advise against them.
Read MoreA study found that colorectal cancer screening could be boosted by using a rapid, accurate app-read smartphone FIT.
Read MoreA new research study identifies lncRNAs CBR3-AS1 and PCA3 as significantly overexpressed in gastric cancer tissues.
Read MoreForesight Diagnostics and QIAGEN have entered a global partnership to develop and commercialize a companion diagnostic kit for lymphoma.
Read MoreGuardant Health’s Shield MCD test has received FDA Breakthrough Device designation for its ability to detect multiple cancer types.
Read MorePersonalis, Inc. unveiled promising new clinical data from the PREDICT DNA and SCANDARE studies at ASCO 2025.
Read MoreNew Day Diagnostics has launched ColoHealth, a physician-mediated blood test for colorectal cancer screening.
Read MoreLabcorp has expanded its precision oncology portfolio with new tests for solid tumors and blood cancers to support diagnostic development.
Read MoreSAGA Diagnostics has launched Pathlight, a groundbreaking multi-cancer blood test for ultra-sensitive detection of MRD.
Read MoreHologic and Biotheranostics unveiled new data showing that the Breast Cancer Index (BCI) test improves treatment decision-making.
Read MoreForesight Diagnostics announced the independent validation of its CLARITY MRD assay, showing strong prognostic performance.
Read MoreA strategic partnership has formed to accelerate the development a test for early ovarian cancer diagnosis using AI-powered analytics.
Read MoreResearchers developed an AI-driven blood test, ARTEMIS-DELFI, that detects pancreatic cancer treatment response faster and more accurately.
Read MoreThe FDA has approved Roche’s VENTANA MET (SP44) RxDx Assay, the first companion diagnostic for lung cancer.
Read MoreA groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
Read More